Download PDF
Homœopathic Links 2023; 36(04): 266-280
DOI: 10.1055/s-0043-1771254
Original Article

Homoeopathic Pathogenetic Trial of Catharanthus roseus: A Multicentric, Double-Blind, Randomized, Placebo-Controlled Trial

Pritha Mehra
1   Drug Proving Research, Central Council for Research in Homoeopathy, New Delhi, India
,
Lipipushpa Debata
2   Homoeopathic Drug Research Institute, Lucknow under Central Council for Research in Homoeopathy, New Delhi, India
,
Amulya R. Sahoo
3   Drug Proving Unit, Bhubaneswar under Central Council for Research in Homoeopathy, New Delhi, India
,
B. S. J. Rajakumar
4   Regional Research Institute of Homoeopathy, Gudivada under Central Council for Research in Homoeopathy, New Delhi, India
,
Ashish Mahajan
5   Central Research Institute of Homoeopathy, Jaipur under Central Council for Research in Homoeopathy, New Delhi, India
,
Bhopal S. Arya
6   DDPR Central Research Institute of Homoeopathy, Noida under Central Council for Research in Homoeopathy, New Delhi, India
› Author Affiliations Funding This study was supported by the Central Council for Research in Homoeopathy under the Ministry of AYUSH.
› Further Information
    Permissions and Reprints

Abstract

Medicinal plants have a long history of usage in traditional medicine, and Catharanthus roseus L. (G.) Don is one such plant. However, to understand its homoeopathic therapeutic effect, it was important to find the pathogenetic powers by conducting a drug proving trial. To elicit the pathogenetic response of C. roseus in homoeopathic potencies on healthy human provers, a multicenter, randomized, double-blind, placebo-controlled trial was conducted at four centers under the Central Council for Research in Homoeopathy. The proving trial involved 60 relatively healthy provers. All provers were given placebo in the first phase. After randomization, 40 provers in the intervention group were given C. roseus in 6C, 12C, 30C, and 200C potencies in four phases. The control group of 20 provers were administered unmedicated globules in all the phases. A maximum of 12 doses divided into 4 doses/day for 3 days were administered in all phases of the trial. The symptoms and signs manifested during the trial were noted down by the provers, elaborated by the proving masters, and the data were finally processed at the proving-cum-data processing cell of the Council. Among the 40 provers of the verum group, only 15 provers manifested 22 pathogenetic and 10 placebo symptoms, whereas 30 symptoms were reported by 12 provers in the control group. The symptoms have been manifested predominantly in 200C potency. The pathogenetic response elicited during this trial expands the scope of the use of C. roseus and needs to be further validated by a clinical verification study.

Keywords

Catharanthus roseus - double blind - drug proving - homoeopathic pathogenetic trial - homoeopathy - pathogenetic effect - placebo


Publication History

Article published online:
27 October 2023

© 2023. Thieme. All rights reserved.

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Mishra JN, Verma NK. A brief study on Catharanthus roseus: a review. Int J Res Pharm urn Sci 2017; 2 (02) 20-23
    PubMedGoogle Scholar
  • 2 Naeem M, Aftab T, Idrees M, Alam MM, Khan MMA, Uddin M. Plant efficacy and alkaloids production in Sadabahar (Catharanthus roseus L.): role of potent PGRs and mineral nutrients. In: Naeem M, Aftab T, Khan MMA. eds. Catharanthus roseus: Current Research and Future Prospects. Cham: Springer; 2017
    Google Scholar
  • 3 Ramya S, Govindaraji V, Kannan KN, Jayakumararaj R. In vitro evaluation of antibacterial activity using crude extracts of Catharanthus roseus L. (G.) Don. Ethnobotanical Leaflets 2008; 12: 1067-1072
    PubMedGoogle Scholar
  • 4 Aziz S, Saha K, Sultana N, Nur HP. et al. Comparative studies of elemental composition in leaves and flowers of Catharanthus roseus growing in Bangladesh. Asian Pac J Trop Biomed 2016; 6 (01) 50-54
    CrossrefPubMedGoogle Scholar
  • 5 Gajalakshmi S, Vijayalakshmi S, Devi RV. Pharmacological activities of Catharanthus roseus: a perspective review. Int J Pharma Bio Sci 2013; 4 (02) 431-439
    PubMedGoogle Scholar
  • 6 Kale A. A scientific review on Sadaphuli in Ayurveda. J Ayurveda Integr Med Sci 2021; 6 (03) 94-99
    PubMedGoogle Scholar
  • 7 Shikhare S. Catharanthus roseus: a symbol of hope for cancer patients. Oncol & Cancer Case Rep 2020; 6 (03) 1-1
    PubMedGoogle Scholar
  • 8 Kushwaha UR, Nagargoje U. Evaluation of anti-leukemic activity of potentised Catharanthus roseus: an in-vitro study. Indian J Res Homoeopathy. 2011; 5 (04) 7-15
    CrossrefPubMedGoogle Scholar
  • 9 Schroyens F. Blueprint for a New Repertory Synthesis. London: Homeopathic Book Publishers; 1990
    Google Scholar
  • 10 Gupta VK. Catharanthus roseus: proving and clinical verification. Homœopathic Links. 2013; 26: 201-203
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Khurana A, Manchanda R, Mittal R, Taneja D, Haselen R. Homoeopathic drug proving: randomised double-blind placebo-controlled trial. Indian J Res Homoeopath. 2015; 9: 3-11
    CrossrefPubMedGoogle Scholar
  • 12 Research Randomizer. About. Accessed February 21, 2023 at: https://www.randomizer.org/about/
    PubMedGoogle Scholar
  • 13 Homoeopathic Pharmacopoeia of the United States. HPCUS Proving Guidelines. Accessed January 17, 2023 at: https://www.hpus.com/HPCUS-Proving-Guidelines-2015.pdf
    PubMedGoogle Scholar
  • 14 Schulz KF, Altman DG, Moher D. CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med 2010; 8: 18
    CrossrefPubMedGoogle Scholar
  • 15 Dean ME, Coulter MK, Fisher P, Jobst K, Walach H. Reporting data on homeopathic treatments (RedHot): a supplement to CONSORT. Homeopathy 2007; 96 (01) 42-45
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Lewis JA, Jonsson B, Kreutz G, Sampaio C, van Zwieten-Boot B. Placebo-controlled trials and the Declaration of Helsinki. Lancet 2002; 359 (9314) 1337-1340
    CrossrefPubMedGoogle Scholar
  • 17 Dantas F, Fisher P, Walach H. et al. A systematic review of the quality of homeopathic pathogenetic trials published from 1945 to 1995. Homeopathy 2007; 96 (01) 4-16
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Hahnemann S. Organon of Medicine. 5th and 6th ed. New Delhi: B Jain; 2010
    Google Scholar
  • 19 Hahnemann S. Materia Medica Pura. Vol. 1. Reprinted. New Delhi: B Jain Publishers; 1986: 16
    Google Scholar
  • 20 Teut M, Dahler J, Hirschberg U, Luedtke R, Albrecht H, Witt CM. Homeopathic drug proving of Okoubaka aubrevillei: a randomised placebo-controlled trial. Trials 2013; 14: 96
    CrossrefPubMedGoogle Scholar